Adagene Inc. (ADAG) stock analysis

Healthcare · Biotechnology

From the 20-F filed 2026-04-01

Business type: Asset play

How it makes money

It earns revenue by licensing its proprietary antibody technology and intellectual property to pharmaceutical partners in exchange for upfront and milestone payments.

As a clinical-stage biotechnology company, it has not brought any therapeutic products to market and does not currently generate revenue from product sales. Instead, its business model relies on monetizing its computational antibody discovery platform through collaborations.

Earnings are primarily driven by the timing and successful execution of these licensing agreements. Revenue fluctuates based on its ability to reach specific development milestones or sign new out-licensing deals with global partners.

What protects it: the moat

It asserts that its competitive advantage resides in its proprietary Dynamic Precision Library platform and its internal intellectual property portfolio.

The company claims it maintains an edge through a proprietary technology interface that allows it to engineer antibodies that are otherwise intractable to traditional methods. It relies on the development and protection of this intellectual property to keep competitors at bay.

Management maintains these assets are central to its business, though the efficacy of this protection against larger, better-funded pharmaceutical competitors remains a claim of the company.

What growth costs

It must heavily reinvest in research and development, clinical trials, and personnel to advance its pipeline and sustain operations.

Growth costs are defined by the intensive capital requirements of biotech R&D. The company incurs significant expenses to advance its product candidates, such as ADG126, through phase 1 and phase 2 clinical development.

Beyond R&D, it must fund the expansion of its global operations, contract research organizations, and administrative infrastructure. It expects these costs to increase as it progresses toward potential commercialization.

What could damage it

A shift in the PRC government’s regulatory stance or restrictions on foreign investment could hinder its ability to operate or access international capital markets.

Because it relies on a structure with significant operations in China, the company is vulnerable to the oversight and discretionary power of the PRC government. Policies regarding cybersecurity, data privacy, or the ability to list on foreign exchanges could change abruptly.

If the government restricts its ability to conduct cross-border business or access capital, it would be unable to fund the R&D and clinical trials necessary to sustain its licensing-based revenue model, effectively halting its operations.

About Adagene Inc.

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Other companies in Biotechnology